- Home
- CERO vs SNPX Comparison
CERO vs SNPX Comparison
Compare CERO & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- SNPX
- Stock Information
- Founded
- CERO 2017
- SNPX 2012
- Country
- CERO United States
- SNPX United States
- Employees
- CERO N/A
- SNPX N/A
- Industry
- CERO
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- CERO
- SNPX Health Care
- Exchange
- CERO Nasdaq
- SNPX Nasdaq
- Market Cap
- CERO 3.1M
- SNPX 3.1M
- IPO Year
- CERO N/A
- SNPX N/A
- Fundamental
- Price
- CERO $0.89
- SNPX $2.33
- Analyst Decision
- CERO Strong Buy
- SNPX Strong Buy
- Analyst Count
- CERO 1
- SNPX 1
- Target Price
- CERO $11.00
- SNPX $14.00
- AVG Volume (30 Days)
- CERO 4.4M
- SNPX 11.5K
- Earning Date
- CERO 04-15-2025
- SNPX 05-14-2025
- Dividend Yield
- CERO N/A
- SNPX N/A
- EPS Growth
- CERO N/A
- SNPX N/A
- EPS
- CERO N/A
- SNPX N/A
- Revenue
- CERO N/A
- SNPX N/A
- Revenue This Year
- CERO N/A
- SNPX N/A
- Revenue Next Year
- CERO N/A
- SNPX N/A
- P/E Ratio
- CERO N/A
- SNPX N/A
- Revenue Growth
- CERO N/A
- SNPX N/A
- 52 Week Low
- CERO $0.53
- SNPX $1.84
- 52 Week High
- CERO $171.00
- SNPX $5.38
- Technical
- Relative Strength Index (RSI)
- CERO 49.91
- SNPX 49.26
- Support Level
- CERO $0.53
- SNPX $2.05
- Resistance Level
- CERO $1.42
- SNPX $2.21
- Average True Range (ATR)
- CERO 0.12
- SNPX 0.18
- MACD
- CERO 0.07
- SNPX 0.04
- Stochastic Oscillator
- CERO 40.19
- SNPX 79.51
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.